Back to Search
Start Over
Prevention of autoimmune but not allogeneic destruction of grafted islets by different therapeutic strategies
- Source :
- Journal of Molecular Medicine. Jan, 1999, Vol. 77 Issue 1, p226, 4 p.
- Publication Year :
- 1999
-
Abstract
- Byline: B. Kuttler (1), K. Rosing (1), M. Lehmann (2), J. Brock (2), H. J. Hahn (1) Keywords: Key words BB rat; Islet transplantation; Rejection; Disease recurrence; Immunotherapy Abstract: Grafting autoimmune-diabetic recipients with allogeneic islets, graft rejection and disease recurrence as major problems of reaching indefinite survival and tolerance induction have to be solved. Anti-CD25 and anti-CD4 monoclonal antibodies were successfully used after allogeneic islet transplantation in experimentally diabetic rats. A temporary anti-CD25 therapy also prevented disease recurrence in autoimmune-diabetic BB rats, while this was not yet reported for an anti-CD4 treatment. In autoimmune-diabetic NOD mice disease recurrence can be successfully treated using an anti-CD4 monoclonal antibody. We, therefore, compared the efficacy of a short-term anti-CD25 and anti-CD4 treatment regarding the prevention of allograft rejection and disease recurrence in autoimmune-diabetic BB/OK rats. Both monoclonal antibodies were combined with low doses of Cyclosporin A. Untreated BB/OK rats relapsed into hyperglycaemia within 3 weeks independent of the islet donor, LEW.1A, LEW.1BB/OK or BB/OK rats. However, after grafting MHC-identical allogeneic (LEW.1BB/OK) or syngeneic (BB/OK) islets we observed about 30% spontaneous acceptance. Both the anti-CD25 and anti-CD4 therapy significantly prolonged the survival of allogeneic grafted islets. After MHC-identical allogeneic and syngeneic islet transplantation the temporary immunotherapy increased the proportion of permanent acceptors to 63% and 75%, respectively. The efficacy of both treatment strategies in prolonging allograft survival and prevention of disease recurrence was identical. In summary, anti-CD25 as well as anti-CD4 therapy prevented autoimmune but not allogeneic islet destruction in autoimmune-diabetic BB/OK rats. In conclusion, targeting different immune cells by monoclonal antibodies with different specificities can lead to very similar results with respect to an interruption of allograft rejection and autoimmune reaction. Author Affiliation: (1) Institute of Pathophysiology, (formerly Institute of Diabetes 'G. Karsch') Ernst-Moritz-Arndt-University of Greifswald, Greifswalder Strasse 11a, D-17495 Karlsburg, Germany, DE (2) Institute of Medical Biochemistry, University of Rostock, Germany, DE
- Subjects :
- Science and technology
Subjects
Details
- Language :
- English
- ISSN :
- 09462716
- Volume :
- 77
- Issue :
- 1
- Database :
- Gale General OneFile
- Journal :
- Journal of Molecular Medicine
- Publication Type :
- Academic Journal
- Accession number :
- edsgcl.163427505